This report was first published by Endpoints News. To see the original version, click here
An under-the-radar Wuhan-based biotech startup says that its gene therapy for an inherited form of vision loss has generated early but promising results in a handful of patients.
The startup, Zhongmou Therapeutics, has attracted little public notice in the West and appears to have raised only a fraction of what is typical for Western companies working on gene therapies.
您已閱讀6%（461字），剩余94%（6874字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。